intermediate grade lymphoma

Summary

Summary: One of the three major prognostic groupings for non-Hodgkin lymphomas as proposed in the Working Formulation of the Non-Hodgkin's Lymphoma Pathologic Classification Project sponsored by the National Cancer Institute (1981). Lymphomas falling within this group have an intermediate survival potential.

Top Publications

  1. ncbi [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:448-51. 2004
  2. pmc Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China
    Minrui Li
    Division of Gastroenterology, The First Affiliated Hospital, Sun Yat Sen University Guangzhou 510080, P R China
    Int J Clin Exp Pathol 7:2718-28. 2014
  3. ncbi Multicentric lymphoma in a giant anteater (Myrmecophaga tridactyla)
    Adrien W D Sanches
    Veterinary Hospital, Laboratory of Veterinary Pathology, Universidade do Contestado, R Roberto Elhke, 85, Centro, Canoinhas, SC, CEP 89460 000, Brazil
    J Zoo Wildl Med 44:186-8. 2013
  4. ncbi Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?
    Mariano Provencio
    Servicio de Oncologia Medica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
    Clin Transl Oncol 14:386-90. 2012
  5. ncbi Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?
    P Mollee
    Bone Marrow Transplant Service, Princess Margaret Hospital, Toronto, Canada
    Bone Marrow Transplant 31:953-60. 2003
  6. ncbi [Gastric non-Hodgkin lymphoma: guidelines for the therapeutic approach]
    Marcello Bellini
    Dipartimento di Chirurgia Generale e D Urgenza Università degli Studi di Napoli Federico II
    Chir Ital 55:391-7. 2003
  7. ncbi 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    C I Chen
    The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Bone Marrow Transplant 30:885-91. 2002
  8. ncbi Autologous hematopoietic transplantation for low-grade lymphomas
    J G Gribben
    Department of Adults Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cytotherapy 4:205-15. 2002
  9. ncbi [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy]
    Roberto Bettini
    Universita dell Insubria, Ospedale di Circolo, Varese
    Recenti Prog Med 94:494-500. 2003
  10. ncbi Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
    Fausto Rossini
    Hematology Unit, Ospedale S Gerardo, Via Donizetti 106, 20052 Monza MI, Italy
    Cancer 100:350-5. 2004

Research Grants

Scientific Experts

Detail Information

Publications49

  1. ncbi [Treatment of lymphoma patients with fludarabine-based regimens: a report of 29 cases]
    Hui Qiang Huang
    Department of Medical Oncology, Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, 510060, PR China
    Ai Zheng 23:448-51. 2004
    ..Significantly higher response rate can be yielded by combined regimen such as FN, FMD, and FC, etc. The purpose of this study was to investigate the efficacy and toxicity of fludarabine-based regimen for patients with lymphoma in China...
  2. pmc Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China
    Minrui Li
    Division of Gastroenterology, The First Affiliated Hospital, Sun Yat Sen University Guangzhou 510080, P R China
    Int J Clin Exp Pathol 7:2718-28. 2014
    ..Univariate and multivariate analysis revealed that performance status, lactate dehydrogenase (LDH) level and histological type were independent prognostic factors for PGIL. ..
  3. ncbi Multicentric lymphoma in a giant anteater (Myrmecophaga tridactyla)
    Adrien W D Sanches
    Veterinary Hospital, Laboratory of Veterinary Pathology, Universidade do Contestado, R Roberto Elhke, 85, Centro, Canoinhas, SC, CEP 89460 000, Brazil
    J Zoo Wildl Med 44:186-8. 2013
    ..The neoplasia was classified as a form of multicentric lymphohistiocytic lymphoma (Rappaport Classification) and as an intermediate grade lymphoma (National Cancer Institute Working Formulation).
  4. ncbi Are there any significant variations in the clinical or histological presentation of lymphoid pathologies over the course of time in Spain?
    Mariano Provencio
    Servicio de Oncologia Medica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
    Clin Transl Oncol 14:386-90. 2012
    ..Little data is available concerning variations in the clinical characteristics of lymphoid neoplasms at presentation. We decided to investigate whether any variations in these characteristics had occurred in Spain during the last few years...
  5. ncbi Why aren't we performing more allografts for aggressive non-Hodgkin's lymphoma?
    P Mollee
    Bone Marrow Transplant Service, Princess Margaret Hospital, Toronto, Canada
    Bone Marrow Transplant 31:953-60. 2003
    ..New approaches to allogeneic transplantation, including the use of matched-unrelated donors and reduced-intensity conditioning regimens, may expand the applicability of this potentially curative modality...
  6. ncbi [Gastric non-Hodgkin lymphoma: guidelines for the therapeutic approach]
    Marcello Bellini
    Dipartimento di Chirurgia Generale e D Urgenza Università degli Studi di Napoli Federico II
    Chir Ital 55:391-7. 2003
    ..Patients with low and intermediate grade lymphoma (according to the working formulation) had a longer survival (83% and 71%, respectively) than patients ..
  7. ncbi 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma
    C I Chen
    The University of Toronto Autologous Blood and Marrow Transplant Program, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Bone Marrow Transplant 30:885-91. 2002
    ..We conclude that high-dose therapy with ABMT is appropriate for lymphoma patients even when disease reduction requires repeated numbers of salvage regimens...
  8. ncbi Autologous hematopoietic transplantation for low-grade lymphomas
    J G Gribben
    Department of Adults Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Cytotherapy 4:205-15. 2002
    ..transplantation (SCT) has become the treatment of choice for patients with relapsed chemo-sensitive intermediate grade lymphoma, but its role in the treatment of low-grade lymphomas and in selected patients in first remission ..
  9. ncbi [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy]
    Roberto Bettini
    Universita dell Insubria, Ospedale di Circolo, Varese
    Recenti Prog Med 94:494-500. 2003
    ..We investigated whether the IPI also had prognostic value for NHL patients with a low grade malignancy or high grade malignancy according to the WF...
  10. ncbi Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone
    Fausto Rossini
    Hematology Unit, Ospedale S Gerardo, Via Donizetti 106, 20052 Monza MI, Italy
    Cancer 100:350-5. 2004
    ..In the CEOP regimen, epirubicin was substituted for doxorubicin to reduce cardiotoxicity...
  11. ncbi Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma
    Jeanette K Doorduijn
    Department of Hematology, Erasmus MC Rotterdam, The Netherlands
    Haematologica 89:1109-17. 2004
    ..We analyzed the costs of therapy and follow-up of patients with NHL treated with CHOP with or without G-CSF prophylaxis...
  12. ncbi Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma
    Elizabeth A Chrischilles
    Department of Epidemiology, College of Public Health, University of Iowa, Iowa City 52242, USA
    Cancer Control 10:396-403. 2003
    ....
  13. ncbi Treatment results of radiotherapy for malignant lymphoma of the orbit and histopathologic review according to the WHO classification
    Masatoshi Hasegawa
    Department of Radiology and Radiation Oncology, Gunma University School of Medicine, Maebashi, Japan
    Int J Radiat Oncol Biol Phys 57:172-6. 2003
    ..To analyze the results of radiotherapy (RT) for malignant lymphoma of the orbit and to evaluate them compared with the World Health Organization (WHO) classification published in 2001...
  14. ncbi Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck
    Takeshi Nishioka
    Department of Radiology, Hokkaido University School of Medicine, Kita 15, Nishi 7, Kita ku, Sapporo 060 8648, Japan
    Int J Radiat Oncol Biol Phys 60:847-52. 2004
    ....
  15. ncbi [Treatment of moderate-grade and high-grade malignant lymphoma with autologous hematopoietic stem cell transplantation]
    An Lan Wang
    Hunan Tumor Hospital, Changsha, Hunan, PR China
    Ai Zheng 22:1317-20. 2003
    ..The purpose of this study was to investigate the effectiveness of HDCT combined with radiotherapy supported by HSCT in treatment of poor- prognostic moderate-grade and high-grade malignant lymphoma...
  16. ncbi Orofacial non-Hodgkins lymphoma in Nigerians
    Vincent Ifechukwukwu Ugboko
    Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, College of Health Sciences, Obafemi Awolowo University, Ile Ife, Nigeria
    J Oral Maxillofac Surg 62:1347-50. 2004
    ..In this study, we sought to determine the occurrence of primary non-Hodgkins lymphoma (NHL) in the oral and maxillofacial region among Nigerians...
  17. ncbi Splenic non-Hodgkin's lymphoma presenting as recurrent kidney stones -- an "incidentaloma"?
    Kaushik Doshi
    Jamaica Hospital Medical Center, Jamaica, NY, USA
    Proc West Pharmacol Soc 51:55-7. 2008
    ..However, further investigation led to the discovery of splenic lymphoma, which was asymptomatic earlier but may have manifested symptoms that mimicked renal colic...
  18. ncbi Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin's lymphoma: a review of 59 consecutive cases treated at a single institute
    Miyuki Akutsu
    Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan
    Oncol Res 17:137-49. 2008
    ..Further evaluation and prospective studies of the TCC-NHL-91 are warranted...
  19. ncbi Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma
    Roberto Rodriguez
    Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California 91001, USA
    Biol Blood Marrow Transplant 12:1326-34. 2006
    ....
  20. ncbi MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas
    A J M Ferreri
    Medical Oncology Unit, San Raffaele H Scientific Institute, Universita Vita Salute San Raffaele, Milan, Italy
    Neurology 66:1435-8. 2006
    ..Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 +/- 7%) was obtained...
  21. ncbi Primary lymphoma of the liver--a case report
    S Chawla
    Tata Main Hospital, Jamshedpur, Jharkhand
    Indian J Pathol Microbiol 47:533-5. 2004
    ..The case is being reported for its rarity and the clinical importance of recognizing such cases because of excellent prognosis...
  22. ncbi Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens
    Kirit M Ardeshna
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 130:363-72. 2005
    ..This analysis indicates that patients with malignant lymphomas, who have PD on 1 degrees ST, are not rescued by subsequent salvage regimens. They should either be treated palliatively or novel approaches should be explored...
  23. ncbi Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
    S Monfardini
    Division of Medical Oncology, Azienda Ospedale Universita, Padova
    Ann Oncol 16:1352-8. 2005
    ..The aim of this study was to evaluate the efficacy and tolerability of vinorelbine and prednisone in frail elderly patients with NHL...
  24. ncbi Diffuse primary non-Hodgkin's lymphoma of the cranial vault
    K Aquilina
    Department of Neurosurgery, Beaumont Hospital, Dublin, Eire
    Br J Neurosurg 18:518-23. 2004
    ..The other nine reported cases of primary skull vault lymphoma are reviewed. The diffuse vault infiltration as well as the multiple intracranial, scalp and temporalis muscle masses renders this case unique...
  25. ncbi A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results
    B Ribba
    Institute for Medical Biomathematics, 10 Hate ena Street, P O B 282, 60991 Bene Ataroth, Israel
    Bull Math Biol 67:79-99. 2005
    ..Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system...
  26. ncbi High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality
    Punit D Wadhwa
    Department of Medicine, Comprehensive Cancer Center of the University Hospitals of Cleveland Case Western Reserve University, Cleveland, Ohio 44106, USA
    Biol Blood Marrow Transplant 11:13-22. 2005
    ..BEP with or without IFR is a highly effective and well-tolerated regimen in the relapsed/refractory lymphoma setting. It has low morbidity and transplant-related mortality and a low incidence (3%) of posttransplantation malignancy...
  27. ncbi Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma
    Huda Salman
    Department of Oncology, Montefiore Medical Center, Bronx, NY 10461, USA
    Am J Clin Oncol 26:338-43. 2003
    ..Substitution of idarubicin for doxorubicin in this setting, therefore, is not associated with an improved response rate...
  28. ncbi First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, 37203, USA
    Clin Lymphoma 4:36-42. 2003
    ..This regimen provides a treatment option for elderly patients who are not considered candidates for standard CHOP/rituximab chemotherapy...
  29. ncbi High-dose chemotherapy and autologous bone marrow transplantation in diffuse intermediate- and high-grade non-Hodgkin lymphoma
    Thierry Philip
    Bone Marrow Transplant Department, Centre Leon Berard, 28 rue Laennec, 69008, Lyon, France
    Crit Rev Oncol Hematol 41:213-23. 2002
    ..Timing and epidemiology are reviewed before the various clinical situations (primary refractory partial responses, complete responses and relapses). The Lyon consensus conference held in 1998 has also extensively been used and quoted...
  30. ncbi External beam radiation therapy in the treatment of patients with extranodal stage IA non-Hodgkin's lymphoma
    Jonathan H Briggs
    Department of Radiation Oncology, University of Arizona Cancer Center, 1501 North Campbell Avenue, Tucson, AZ 85724, U S A
    Am J Clin Oncol 25:34-7. 2002
    ..External beam radiation therapy is a highly effective treatment for stage IA NHL found in extranodal sites...
  31. ncbi Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high grade non-Hodgkin's lymphoma
    R S Stein
    Department of Medicine, Vanderbilt University School of Medicine, and VA Medical Center, Nashville, TN 37232, USA
    Leuk Lymphoma 40:521-8. 2001
    ..Survival was significantly inferior to the survival observed in a concurrent series of patients with intermediate grade lymphoma, 34% +/- 6%, p < .05...
  32. ncbi Topotecan (hycamptin) and topotecan-containing regimens in the treatment of hematologic malignancies
    M Beran
    Department of Leukemia, Division of Medicine, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard Box 61, Houston, Texas 77030 4095, USA
    Ann N Y Acad Sci 922:247-59. 2000
    ..Topotecan combined with paclitaxel is promising in low-/intermediate-grade lymphomas. The activity of topotecan justifies further evaluation of topotecan-containing combination regimens, particularly in MDS/CMML and acute leukemias...
  33. ncbi High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry
    C D Williams
    Department of Hematology, University College Hospital, London, United Kingdom
    J Clin Oncol 19:727-35. 2001
    ....
  34. ncbi A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL
    I W Flinn
    The Johns Hopkins University, Baltimore, Maryland, USA
    Ann Oncol 11:691-5. 2000
    ..The objectives of this study were to determine the maximum tolerated dose (MTD) of liposomal daunorubucin with CVP (COP-X) and the tolerability of the regimen in patients with indolent lymphoma...
  35. ncbi Radiation therapy in the treatment of lymphoma
    J Yahalom
    Memorial Sloan Kettering Cancer Center, and Radiation Oncology in Medicine, Cornell University Medical College, New York, NY, USA
    Curr Opin Oncol 11:370-4. 1999
    ..Recent studies established the following points: 1) For early-stage intermediate grade lymphoma, combined modality is the treatment of choice...
  36. ncbi Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
    I F Khouri
    Department of Hematology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:2817-24. 1998
    ....
  37. ncbi Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B
    D R Budman
    Cancer and Leukemia Group B, Chicago, IL, USA
    J Clin Oncol 15:3275-9. 1997
    ....
  38. ncbi Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma
    Richard B Wilder
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:601-5. 2002
    ....
  39. ncbi Clinical presentation and treatment of secondary orbital lymphoma
    Bita Esmaeli
    Section of Ophthalmology, Department of Plastic Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ophthal Plast Reconstr Surg 18:247-53. 2002
    ....
  40. ncbi Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349)
    Douglas W Blayney
    Wilshire Oncology Medical Group, Inc, Pasadena, CA, USA
    J Clin Oncol 21:2466-73. 2003
    ....
  41. ncbi [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma]
    Zhong Yu Yuan
    Cancer Center, Sun Yat Sen University, Guangzhou, Guangdong, PR China
    Ai Zheng 22:393-6. 2003
    ..The study was performed to compare the efficacy and toxicity of CHO (without prednisone) and standard CHOP regimen...
  42. ncbi Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma
    L M Cunningham
    The Western Australian Centre for Pathology and Medical Research, Perth, WA, Australia
    Leuk Lymphoma 44:251-5. 2003
    ..lymphoma (B-cell DLCL n = 46, other aggressive histologies n = 17), Hodgkin's disease (n = 44) or low/intermediate grade lymphoma (n = 46), compared to healthy controls...
  43. ncbi Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy
    Sylvie Martinet
    Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland
    Int J Radiat Oncol Biol Phys 55:892-8. 2003
    ..To assess the outcome and prognostic factors in patients with orbital lymphoma treated by radiotherapy (RT)...
  44. ncbi Prognostic factors in localized aggressive non-Hodgkin's lymphoma
    Suleyman Alici
    Institute of Oncology, Istanbul University, Istambul, Turkey
    Am J Clin Oncol 26:1-5. 2003
    ..These factors need to be evaluated for analyzing the outcome of treatment and to identify better therapeutic strategies...
  45. ncbi Single institute experience of chemotherapy and adjuvant radiotherapy for localized aggressive non-Hodgkin's lymphoma: retrospective analysis of the clinical efficacy of radiation therapy
    Takeshi Kodaira
    Department of Radiation Oncology, Aichi Cancer Center, Nagoya, Aichi, Japan
    Am J Clin Oncol 25:612-8. 2002
    ..Limited-field radiation may have possible advantages in toxicity if it does not lead to worsening of the outcome, although a conclusive result could not be obtained by the current analysis...
  46. ncbi Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study
    Michael Crump
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada
    Leuk Lymphoma 43:1581-7. 2002
    ..Other doses and schedules combining topo I and II inhibitors, or topo I inhibitors with alkylating agents, should be explored with the addition of hematopoietic growth factors in this patient population...
  47. ncbi Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up
    B Bolwell
    Department of Hematology and Medical Oncology, Taussig Cancer Center, and Transplant Center, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk R32, Cleveland, Ohio 44195, USA
    Bone Marrow Transplant 29:673-9. 2002
    ..We conclude that patients with NHL treated with ABMT, if in CR 5 years post transplant, are at very low risk of relapse with extended follow-up, suggesting the possibility of cure for all histologies, including those with low grade NHL...
  48. ncbi Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493)
    Joseph A Sparano
    Albert Einstein Comprehensive Cancer Center Montefiore Medical Center, Bronx, NY, USA
    Blood 100:1634-40. 2002
    ..It is unlikely that infusional therapy as used in this study produces a 25% or greater relative improvement in FFS compared with standard therapy...
  49. ncbi [Syndrome of persistent generalized lymphadenopathy with development into a gastric lymphoma]
    E Aguilar Ligorit
    , Servei Valencia de Salut, Hospital Clinic Universitari, Valencia
    Sangre (Barc) 35:64-8. 1990
    ..Sixteen months after diagnosis, he developed intermediate-grade lymphoma of the stomach. Partial response was achieved by chemotherapy, and the patient presented pulmonary and meningeal tuberculosis which led him to exitus...

Research Grants1

  1. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2002
    ..peripheral blood stem cell transplantation (PBSCT) in the setting of relapsed and refractory low and intermediate grade lymphoma. Finally, quantitative clonotypic PCR will be used to determine if a reservoir of clinically occult ..